相关实验视频

Updated: Jun 28, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

阿西米尼布维持抗体依赖的细胞细胞毒性对白血病爆发

Samuel J Holzmayer^1,2, Joseph Kauer^1,3,4,5, Jonas Mauermann^1,2

¹Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.

|April 13, 2024

概括

新型阿西米尼布氨酸激酶抑制剂 (TKI) 在B细胞急性淋巴细胞白血病 (B-ALL) 模型中不会干扰抗体依赖细胞细胞毒性 (ADCC). 这一发现表明阿斯基米尼布 (asciminib) 的存在.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

B细胞急性淋巴细胞白血病 (B-ALL) 治疗包括化疗,干细胞移植和氨酸激酶抑制剂 (TKI) 对BCR-ABL1阳性病例.
单克隆抗体 (mAb) 疗法,像rituximab一样,越来越多地用于B-ALL,通过包括抗体依赖细胞细胞毒性 (ADCC) 在内的机制增强结果.
组合疗法 (化疗,TKI) 与mAb介导ADCC的潜在干扰需要进行调查.

研究的目的:

评估TKIs,特别是阿西米尼布在B-ALL细胞系中Rituximab诱导的ADCC的体外影响.
评估阿西米尼布对自然杀手 (NK) 细胞功能的影响,这对ADCC至关重要.

主要方法:

在体外分析B-ALL细胞系 (BCR-ABL1阳性和阴性) 用Rituximab和各种TKI治疗.
评估NK细胞的激活,增殖,脱粒,细胞因子释放和瘤细胞溶解.
将ATP位抑制剂 (达沙替尼,波纳替尼) 与STAMP抑制剂阿斯基米尼布 (asciminib) 的作用进行比较.

主要成果:

选择性全性STAMP抑制剂阿西米尼布在经过测试的B-ALL模型中没有显著损害瑞图西马布介导的ADCC.
相比之下,ATP位抑制的TKI显示出对ADCC的潜在干扰.
观察到阿西米尼布对支持ADCC的NK细胞功能缺乏干扰.

结论:

阿西米尼布在ADCC方面表现出有利的概况,与其他TKI不同.
这些发现支持阿斯基米尼布在B-ALL治疗中与单克隆抗体结合的潜在使用.
需要对阿斯基米尼布在B-ALL的联合治疗中进行进一步的临床研究.

关键词:

这里是TKI TKI.急性淋巴细胞白血病急性淋巴细胞白血病亚斯基明尼比 (asciminib) 是一种 bcr-ablll 这是一个很好的方法.一个单克隆抗体.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...